Also trades as: 0K6R.L (LSE) · $vol 0M
NBIX NASDAQ
Neurocrine Biosciences, Inc.
1W: +2.9%
1M: +4.0%
3M: -19.2%
YTD: +3.9%
1Y: +1.4%
3Y: +32.3%
5Y: +41.6%
$146.00
+0.13 (+0.09%)
Weekly Expected Move ±3.9%
$131
$137
$143
$148
$154
Credit Risk of going bust: lower than 88% of companies Debt: 2.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.30 (down 99.8%), Neurocrine Biosciences, Inc. would be worth roughly what it owes.
Total debt $401.8M against a stock market value of $14.84B.
Distance to default 12.82 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $200.9M (short-term plus half of long-term), stock volatility 34.0%; Altman Z'' 4.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.30 (down 99.8%), Neurocrine Biosciences, Inc. would be worth roughly what it owes.
Total debt $401.8M against a stock market value of $14.84B.
Distance to default 12.82 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $200.9M (short-term plus half of long-term), stock volatility 34.0%; Altman Z'' 4.79. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.45
Bullish
3 bullish
0 neutral
1 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (100)
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?
Healthcare stocks with strong revenue growth and attractive valuations
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Where Will Neurocrine Biosciences Be in 5 Years?
Oppenheimer updates its top 50 buy list, rotating away from big banks
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Congress Asset Management Co. Grows Stake in Neurocrine Biosciences, Inc. $NBIX
Andra AP fonden Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX
Nykredit A S Makes New $5.19 Million Investment in Neurocrine Biosciences, Inc. $NBIX
Bank of America Corp DE Buys New Stake in Neurocrine Biosciences, Inc. $NBIX
Integrated Wealth Concepts LLC Sells 5,703 Shares of Neurocrine Biosciences, Inc. $NBIX
Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX
Engineers Gate Manager LP Increases Holdings in Neurocrine Biosciences, Inc. $NBIX
Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX
Amundi Has $37.16 Million Position in Neurocrine Biosciences, Inc. $NBIX
Allworth Financial LP Buys 6,346 Shares of Neurocrine Biosciences, Inc. $NBIX
Ten healthcare stocks with A-rated valuations and strong revenue growth
Hsbc Holdings PLC Decreases Holdings in Neurocrine Biosciences, Inc. $NBIX
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Continuum Advisory LLC
Azimuth Capital Investment Management LLC Trims Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
46,762 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Corient Private Wealth LP
Allient, Amkor Technology among those added by Fundstrat Granny Shots US Small- & Mid-Cap ETF in quarterly revision
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
B. Metzler seel. Sohn & Co. AG Acquires New Shares in Neurocrine Biosciences, Inc. $NBIX
Allworth Financial LP Invests $2.50 Million in Neurocrine Biosciences, Inc. $NBIX
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
BlackRock Inc. Takes $2.31 Billion Position in Neurocrine Biosciences, Inc. $NBIX
NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?
14,787 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by ABN AMRO Bank N.V.
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Assenagon Asset Management S.A. Has $37.52 Million Holdings in Neurocrine Biosciences, Inc. $NBIX
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
Glenmede Trust Co. NA Has $10.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
NBIX Q2 Earnings Call Highlights: Portfolio Expansion Drives Growth
Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Neurocrine Biosciences Q2 2026 Earnings Preview
Amarin's Q2 Earnings Beat Estimates, Revenues Fall Short
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
STERIS' Q1 Earnings on Deck: What's in Store for the Stock?
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline
Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Here's Why You Should Add Savara Stock to Your Portfolio Now
California Public Employees Retirement System Purchases 25,620 Shares of Neurocrine Biosciences, Inc. $NBIX
Bank of New York Mellon Corp Reduces Position in Neurocrine Biosciences, Inc. $NBIX
Omnicell to Report Q2 Earnings: OmniSphere in Focus
Acadia Gets FDA's Fast Track Tag for Alzheimer's Disease Candidate
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Align Technology to Report Q2 Earnings: Clear Aligner Segment in Focus
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
GSK Discontinues Development of Camlipixant for Refractory Chronic Cough
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Here's Why You Should Add INKT Stock to Your Portfolio Now
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball
NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus
GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
Agilent Strengthens Biopharma Growth Prospects With AI Expansion
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Reasons Why Investors Should Consider Betting on Neurocrine Stock
Zacks.com featured highlights include Neurocrine Biosciences, MYR Group, Block, Delek US Holdings and Dycom Industries
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should Know
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
5 Relative Price Strength Stocks to Buy for the Second Half
Top Stock Picks for Week of June 29, 2026
Neurocrine Biosciences and Ryanair have been highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Neurocrine Biosciences (NBIX)
Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Best Momentum Stocks to Buy for June 24th
New Strong Buy Stocks for June 24th
Best Value Stocks to Buy for June 24th
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys
4basebio Announces Appointment of Chief Financial Officer and Board Changes
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
Neurocrine (NBIX) is an Incredible Growth Stock: 3 Reasons Why